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Letter to the Editor
Am. J. Hum. Genet. 78:1081, 2006
Considerations for Genomewide Association Studies
in Parkinson Disease
To the Editor:
Although the magnitude of a genetic component of Par-
kinson disease (PD [MIM 168600]) remains to be de-
termined, the disease has already shown remarkable ge-
netic heterogeneity, with at least five monogenic forms
identified, the most common of which is LRRK2 (MIM
609007).1 In this issue of The American Journal of Hu-
man Genetics, four investigative teams2–5 report that
they have sought to replicate the findings from a ge-
nomewide association (GWA) study of PD affection by
Maraganore et al.6 Taken together, these four studies
appear to provide substantial evidence that none of the
SNPs originally featured as potential PD loci are con-
vincingly replicated and that all may be false positives.
Furthermore, that the LRRK2 gene was not identified
may be considered a false-negative result. This conclu-
sion is both disappointing and discouraging. The orig-
inal study invested heavily in this venture, with 443 sib-
ling pairs ( ) discordant for PD typed in tier 1np 886
for 198,345 SNPs (172,420,019 genotype calls) and a
tier 2 follow-up typing the strongest 1,892 SNPs in 332
matched case-control unrelated pairs (1,176,772 geno-
types). Because this report is among the first GWA stud-
ies and because the effort appears to have failed to pro-
duce the desired objective, it is worth examining the
implications for GWA studies in general and, specifically,
the significance of this study for PD.
First, let’s examine the original report. Tier 1 of the
original study is founded upon sibling pairs discordant
for PD recruited from the Mayo Clinic in Rochester,
MN. The sample is composed of individuals substan-
tially of northern and central European descent. Dis-
cordant sibling pairs were selected to limit false-positive
results due to population stratification bias.7 Population
differences between case and control samples are rec-
ognized as the primary source of false-positive associ-
ations, and, clearly, every effort to minimize these effects
is to be encouraged. However, in PD there is substantial
evidence for reduced penetrance,8 and the disease eti-
ology is most likely a complex interaction of genetic and
environmental factors.9 Thus, the selection of randomly
ascertained PD cases (often termed “sporadic”) may in-
clude a substantial proportion of cases with little or no
genetic basis for disease, and, even among familial cases,
many unaffected siblings may carry PD risk alleles but
remain unaffected for lack of critical environmental ex-
posure, for essential modifying genes, or for follow-up
to an advanced age. Case identification in tier 1 should
focus on the selection of those most likely to carry the
inherited form of the disease, whereas controls should
be likely non–gene carriers drawn from the same pop-
ulation. Concerns for population stratification might
best be addressed in tier 2 by the genotyping of families
of tier 1 cases and by family-based association studies.
SNPs showing association in these first phases can be
typed in a second unrelated case-control sample as a tier
3, with case enrichment for familial disease when
possible.
Fundamentally, scientific discovery relies first and
foremost upon the independent replication of results.
Investigators seeking to replicate the findings of asso-
ciation studies need to consider whether their sample
provides an appropriate forum for the investigation. Be-
cause the overwhelming majority of SNPs in GWA stud-
ies will not be functionally related to the disease, one
cannot reasonably expect that linkage-disequilibrium
patterns will generalize across diverse ethnic groups.
Thus, one may expect that there may not be replication
for samples recruited from a restricted geographic region
(e.g., Taiwan2). Whereas most of these replication sam-
ples are composed of Europeans (e.g., from Finland,2
Norway and Ireland,3 and the United Kingdom4), a few
reveal minor-allele frequencies that vary from the orig-
inal sample and that may deserve further study. Enrich-
ment for familial PD would also be important, since
none of these replication studies is described as familial
PD.
Genomewide linkage studies have generally not been
successful in finding genes responsible for common com-
plex diseases, and whether GWA studies will prove to
be more successful remains to be determined. There is
at least one important positive precedent of the Mara-
ganore et al.6 study. Notably, all of their single-SNP as-
sociation results (minor-allele frequencies and P values)
are available in two online text files (available from
http://www.journals.uchicago.edu/AJHG/journal/issues/
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v77n5/42619/tableS2new.txt and http://www.journals
.uchicago.edu/AJHG/journal/issues/v77n5/42619/
tableS3new.txt) in the online-only version of the original
article.6 These results can be readily downloaded and
searched for evidence of association with other inter-
esting PD candidate genes. Maraganore and colleagues,
with the Michael J. Fox Foundation, have the oppor-
tunity to establish a precedent for making the entire
GWA study available online, since one may reasonably
expect that true PD risk alleles may be found among the
SNPs with lesser levels of statistical significance. The jury
is still out on whether this GWA study holds important
insights for PD.
DR. RICHARD H. MYERS
Boston University School of Medicine
Boston
Web Resources
The URL for data presented herein is as follows:
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.nlm
.nih.gov/entrez/Omim/ (for PD and LRRK2)
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